The role of percutaneous coronary intervention (PCI) in the treatment of multivessel coronary artery disease (CAD) is still controversial and widely discussed. More liberal use of drug-eluting stents (DES) increased proportion of those patients undergoing PCI procedure, raising a need for more clinical evidence. The recent reported COMPARE II trial showed similar results of Biolimus-eluting Nobori stent (BES) and Everolimus-eluting Xience/Promus stent (EES) at 1-year in an all comers population. We aim to compare safety and efficacy outcomes in patients with multivessel CAD (a pre-specified study subset) treated with BES and EES in COMPARE II trial. Methods: COMPARE II trial is a large randomized, multicentre, non-inferiority trial with total of 2707 patients enrolled at 12 sites across Europe, randomized in 1:2 ratio to the treatment with BES and EES with similar 12 months dual antiplatelet therapy. Primary endpoint was the composite of cardiac death (CD), non-fatal myocardial infarction (MI) and target vessel revascularization (TVR). Results: Total of 683 patients with multivessel CAD have been enrolled in COMPARE II trial, 453 of which in BES and 230 in EES arm. There were no significant differences in baseline characteristics such as age (64.3 vs. 63.7; pϭ0.4), male gender (78.2% vs. 78.7%; pϭ0.9), or presence of diabetes mellitus (23.0% vs. 25.7%; pϭ0.4) in BES and EES arms respectively. The lesion length and reference diameters were also similar. At 12 months, rate of CD (1.1% vs 1.3%; pϭ1.0), MI (4.4% vs 5.7%; pϭ0.5), target lesion revascularization (4.2% vs 2.6%; pϭ0.4), TVR (5.7% vs 3.9; pϭ0.4), target lesion failure (6.8% vs 7.4%; pϭ0.9) and composite of CD, non-fatal MI and TVR (8.6% vs 9.1%; pϭ0.9) were similar in BES and EES arms, Definite and propable stent thrombosis rate up to 12-months was also not different (1.1% in BES vs 1.3% in EES arm; pϭ1.0). Conclusions: Although this substudy was not powered to detect differences between the two stents, the BES with biodegradable polymer, was found as safe and effective as the EES even in this challenging patients population. This adds valuable evidence about clinical outcomes with contemporary DES.
Background: With the introduction of drug eluting stents (DES) in this decade, treatment of patients with STEMI with these devices has emerged as a rational PCI alternative. In spite of the unquestionable benefits of DES in terms of reduction of restenosis and TVR, specific concerns have arisen with regard to their short-and long-term safety. We aim to assess short-and long-term outcomes in STEMI patients treated with Nobori, DES with biodegradable polymer. Methods: NOBORI 2 and eNOBORI are two large, prospective, single-arm, multicenter, registries that enrolled 3067 and 7750 patients respectively, out of which 248 and 703 were STEMI patients. All adverse events were adjudicated by an independent clinical event committee in NOBORI 2, while adjudication in eNOBORI (including stent thrombosis) is ongoing. The primary endpoint was Target Lesion Failure (TLF) defined as a composite of cardiac death (CD), target vessel related myocardial infarction (MI) and target lesion revascularization (TLR). Results: STEMI patients were 60Ϯ13y old, 79% males, 11% with prior MI, 10% with prior PCI and 0.7% with previous cardiac surgery. Multiple vessels were treated in 19.5% of patients. The lesions were complex (60% B2/C type) ostial (10%), calcified (26%), contained thrombus (49%) and 4% required bifurcation treatment. Pre-and post-dilatation were performed in 54% and 29% of lesions respectively. At 1-month, there were no MIs observed. Total of 5 patients died because of cardiac reasons (0.9%) and one TLR (0.17%) and one TVR (0.4%) were found. The TLF rate was 1.0%. In the cohort of patients followed at 3-year, 2 patients suffered a cardiac death (0.8%), 10 had an MI (4.0%) and TLF rate was 6.1%. A total of 96% of the patients were angina free. Regarding stent thrombosis (ST), occurring up to 3 years, total of 4 cases have been detected (1.6%), out of which 3 cases were subacute (1.2%) and one case of late ST (0.4%). There was no very late ST detected at 3 years follow up. Conclusions: Use of Nobori, DES with biodegradable polymer, in the treatment of patients with STEMI was associated with favorable short-and long-term outcomes, confirming its safety and efficacy for the treatment of this high risk patient population. American Heart of Poland, Ustroń, Poland Background: The impact on healing and clinical outcomes of the individual DES components is still under debate. The aim of this study is to assess vascular effects exclusive to the type of antiproliferative drug, eluted via identical biodegradable polymer and platform stents implanted in the porcine model of coronary injury. Methods: A total of 37 stents were implanted with 110% overstretch in coronary arteries of 14 domestic pigs: 13 biodegradable polymer coated paclitaxel eluting stents (BP-PES: LUC-Chopin2, Balton), 16 biodegradable polymer coated everolimus eluting stents (BP-EES, Carlo, Balton) and 8 control bare metal stents (BMS: Chopin2). Following 30 and 90 day observation (7 animals each) control coronary angiography was performed, animals sacrificed and stented segments harvested for histopathological evaluation. 
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Background:
The newer generation drug eluting stents (DES) have shown advantages over first generation DES, particularly relating to long term safety. However, comparative data for contemporary DES are still insufficient. We aim to compare safety and efficacy between Nobori DES, eluting Biolimus A9 from an abluminal biodegradable polymer (BES) and Xience/Promus DES eluting everolimus from a permanent polymer (EES). Methods: COMPARE II, a prospective, randomized (2:1), controlled, multi-centre study, enrolled 2707 patients (1795 BES arm, 912 EES arm) with limited exclusion criteria. The primary endpoint was a composite of safety (cardiac death, non fatal myocardial infarction-MI) and efficacy (target vessel revascularization-TVR) at 1 year. Dual antiplatelet therapy was 12 months for both arms. The primary hypothesis was non-inferiority of BES vs EES. Data were independently monitored and adverse events were adjudicated by an independent clinical event committee. Results: No significant differences were detected for any of the baseline characteristics. The patients (74% male) were ϳ63 years old, 22% had diabetes mellitus, 20% history of MI, 18% and 6% respectively had prior PCI or CABG. In both groups 58% of patients were treated for acute coronary syndrome (21% for STEMI). Lesions complexity was similar (B2/C: 63%), 14% ostial, 6% bifurcated, 20% thrombosed. Lesions were longer in EES (17.7mm vs. 16.4mm in BES, pϭ0.02), while mean number of stents per lesions was similar (1.4Ϯ0.8). The 1 year primary endpoint was 5.2% in BES arm vs 4.8% in EES arm, confirming the hypothesis of non-inferiority hypothesis (pϽ0.0001). There were no significant differences in any of the secondary endpoints: 0.8% vs 0.8% patients suffered cardiac death, 2.8% vs 2.5% had a MI, 2.9% vs 2.2% underwent TVR, and 2.7% vs 2.2% TLR in the BES and EES arm respectively. Definite and probable stent thrombosis rate was 0.8% in BES and 1.0% in EES. Conclusions: In the largest prospective randomised all-comer trial, the Nobori BES is non-inferior compared to the Xience/Promus EES. Primary and secondary endpoints in this real-life population were not significantly different between both stent groups, with similar, low cardiac death and ST rates. SAO PAULO, Brazil, 3 Lifecare Institute of Medical Sciences and Research, Ahmedab, India, Ahmedab, India, 5 Cardiovascular Research Center, São Paulo, Brazil Background: Despite the marked efficacy of first generation drug-eluting stents (DES) on reducing neointimal hyperplasia (NIH), restenosis, and the need for repeat target lesion revascularization (TLR) compared to bare metal stents, concerns regarding deliverability, efficacy, and long-term safety,led to the development of new DES technologies. The BioMime™ device (Meril Life Sciences Pvt. Ltd., Gujarat, India) is a novel DES system that incorporates an ultra-thin stent platform (0,0026Љ strut thickness), a biodegradable polymer and sirolimus. We report the initial human evaluation of the BioMime™ stent for the treatment of diseased coronary vessels. Methods: The meriT-1 trial was a prospective, non-randomized, single-arm, single center first-in-man evaluation of the safety, feasibility and performance of the novel BioMime™ SES for the treatment of coronary lesions. Lesion criteria were single de novo stenosis 50-99% located in native vessels 2.5-3.5mm in diameter and Յ19mm in length. Left main and bifurcation lesions, in-stent restenosis, thrombus and total occlusion were excluded. Clinical follow-up (FU) at 1-8-12 and 24 months, and all patients were assigned to 8-month angiographic FU. Primary endpoint was in-stent late lumen loss (LLL) at 8 months. MACE (major adverse cardiac events) was defined as cardiac death, MI and ischemia-driven TLR. Results: A total of 30 patients/lesions. Mean age 49.9 years, 30% diabetics, and 43% had previous MI. By angiographic analysis, baseline median lesion length, reference diameter and % diameter stenosis: 15.51mm [12.74;20.27 
TCT-578
First-in-human
Conclusions:
In this first-in-human evaluation the novel BioMime™ SES had excellent performance with high procedural success and efficacy on inhibiting NIH at 8 months. There were no MACE or stent thrombosis up to 1 year.
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